SIHUAN PHARM (00460) has obtained approval from the National Medical Products Administration for the new specifications of Childish Injectable, and it is now listed on the market.

SIHUAN PHARM (00460) announced that its subsidiary Meiyen Space Biotechnology (Jilin) Co., Ltd. independently developed a polylactic acid facial filler (marketed as "anti-aging needle") with 6 new approved specifications by the China National Medical Products Administration. This is another important progress for the product after its initial approval, further enhancing the company's market layout in the field of regenerative medical aesthetics. As the only domestic enterprise that holds compliant "anti-aging needle" and "anti-aging needle" regenerative filling products, as well as botulinum toxin, hyaluronic acid needle, and gold micro-needle and other heavyweight Class III medical device medical aesthetics products, SIHUAN PHARM's anti-aging needle uses the core component of poly-L-lactic acid (PLLA) microspheres to achieve the dual effects of "instant filling + long-lasting regeneration". Its unique patented technology ensures regular microsphere shape, uniform particle size, excellent safety and clinical efficacy, with most patients maintaining effective results one year after injection. Prior to this expansion, the product had been approved in three specifications: 45mg/bottle, 75mg/bottle, and 150mg/bottle, respectively suitable for preventive management, combined treatment, and comprehensive rejuvenation needs. The newly approved 60mg/bottle, 80mg/bottle, 100mg/bottle, 110mg/bottle, 120mg/bottle, and 130mg/bottle specifications will further enrich the product selection spectrum. The added value and significance of this specification expansion: 1. Precisely match diverse anti-aging needs: The new specifications fill the dose gap between the original specifications, covering scenarios from mild aging to moderate to severe aging. Whether it is slight improvement in fine areas or moderate fullness requirements in facial contours, personalized treatment can be achieved through precise dosage selection, meeting the segmented needs of different age groups and levels of aging. 2. Optimize clinical operational flexibility: Leveraging the product's characteristic of rapid dissolution within 1 minute, multiple specifications allow doctors to flexibly adjust dilution concentrations and injection doses based on the injection site and treatment level, reducing the complexity of combination therapy, and improving treatment efficiency and safety. 3. Strengthen market competitiveness: Against the backdrop of the continuous growth of the global anti-aging needle market and the fierce competition domestically, the layout of multiple specifications further solidifies SIHUAN PHARM's differentiation advantage in the field of regenerative medical aesthetics, forming a synergistic effect with its "anti-aging needle" and "dual-wave radio frequency" products, enhancing the comprehensive product matrix of light medical aesthetics. 4. Promote the refinement of the industry: This specification expansion responds to the trend in the medical aesthetics industry from "standardized treatment" to "personalized solutions", guiding the industry to focus on individual patient differences through dosage segmentation, providing industry reference for the specification design of regenerative medical aesthetics products, and assisting the industry in upgrading towards high-quality and refined directions. SIHUAN PHARM will rely on its strong channel network covering over 7,000 medical institutions to quickly promote the market launch of the new specifications, continuously empower medical aesthetics product innovation with the research and development gene of pharmaceutical enterprises, provide consumers with safer, more accurate, and diverse anti-aging solutions, and promote the medical aesthetic sector of the group to enter a new stage of scalable growth.